GlaxoSmithKline PLC (NYSE:GSK) shares hit a new 52-week high on Tuesday . The stock traded as high as $45.50 and last traded at $45.43, with a volume of 1,208,518 shares traded. The stock had previously closed at $45.25.

Several brokerages have recently weighed in on GSK. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Tuesday. BNP Paribas reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Sunday. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 28th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, July 27th. Finally, Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $46.86.

The firm has a 50 day moving average price of $43.18 and a 200-day moving average price of $41.63. The firm has a market cap of $109.45 billion and a PE ratio of 2814.37.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Friday, August 12th will be paid a $0.494 dividend. The ex-dividend date is Wednesday, August 10th.

Several hedge funds have added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in GlaxoSmithKline PLC by 5.1% in the fourth quarter. Rhumbline Advisers now owns 26,550 shares of the pharmaceutical company’s stock worth $1,071,000 after buying an additional 1,300 shares during the last quarter. Atlantic Trust Group LLC increased its stake in shares of GlaxoSmithKline PLC by 9.4% in the fourth quarter. Atlantic Trust Group LLC now owns 53,948 shares of the pharmaceutical company’s stock worth $2,177,000 after buying an additional 4,639 shares during the period. Chesapeake Asset Management LLC increased its stake in shares of GlaxoSmithKline PLC by 95.9% in the fourth quarter. Chesapeake Asset Management LLC now owns 66,956 shares of the pharmaceutical company’s stock worth $2,702,000 after buying an additional 32,775 shares during the period. MUFG Americas increased its stake in shares of GlaxoSmithKline PLC by 11.3% in the third quarter. MUFG Americas now owns 73,060 shares of the pharmaceutical company’s stock worth $2,809,000 after buying an additional 7,399 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of GlaxoSmithKline PLC during the fourth quarter worth about $2,835,000.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.